Cookies

Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

Drug discovery

Tools & Techniques Infectious diseases

A Universal Shot

| Derek Gatherer

A universal flu vaccine is possible – but we need bioinformatics to show us the way

Outside the Lab Drug discovery

Taking Cues from the City of Notions

| Chas Bountra

Boston leads the drug discovery field, and the UK could soon follow suit

Tools & Techniques Drug discovery

When is a Negative a Positive?

| Robert S. Kerbel

We need to change attitudes towards publishing "negative" results

Research Field Drug discovery

Chiral Quest

| William Aryitey

A more efficient way to develop 'one-handed' drug molecules

Research Field Cardiovascular

Wait and iPSC

| William Aryitey

iPSCs could protect patients by predicting drug-induced cardiotoxicity

Research Field Drug discovery

Arresting ALS

| Joe Beckman

When it comes to prognosis, the mouse models I use to study amyotrophic lateral sclerosis (ALS) are sadly accurate – like their human counterparts with familial ALS, all mice with these mutations die young. After 20 years of trying – and failing – to find a treatment that could extend life, I was close to giving up, until a new drug candidate came along. Then something amazing happened – a mouse lived.

Research Field Cancer

Cancer Static Shock

| James Strachan

Are the metrics used to measure cancer drug efficacy inherently flawed?

Tools & Techniques Drug discovery

A Story of Shared Science and Solutions

| Niclas Nilsson

Pharma companies are notoriously protective of their intellectual property, so it’s a big deal to open up and give knowledge away for free.

Research Field Cancer

Laser Focus on Brain Cancer

| William Aryitey

How can we get cytotoxic drugs through the blood–brain barrier – without permanent damage?

Research Field Analytical science

Fragment Screening at (Almost) the Speed of Light

| Frank von Delft

The XChem facility offers drug discovery scientists streamlined, highly sensitive fragment screening, by harnessing the power of synchrotron light.

Newsletter

Send me the latest from The Translational Scientist.

Sign up now

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register